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PERSPECTIVE
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        Target validation and selection are critical early steps in 
the drug discovery process as they trigger substantial 
activity and investment to identify potential drug candi-
dates. Antibodies play a crucial role in target selection 
as they provide powerful tools to explore the distribu-
tion and subcellular location of candidate molecules 
and can also be used to explore function. For studies 
of ion channel targets, antibodies are indispensable as 
they allow for direct exploration of the subunit compo-
sition of channel complexes in native tissues using bio-
chemical and anatomical methods. This perspective 
summarizes the application of antibodies to target 
characterization and validation within the context of a 
CNS therapeutic discovery program targeting voltage-
gated K 
+   channels. We also discuss a strategy for the 
development, characterization, and validation of high-
quality antibody reagents to support key activities in 
drug discovery. 
  Ion Channels/Drug Discovery/Immunohistochemistry/
Brain/Epilepsy 
  Target selection is perhaps the most critical step in early 
drug discovery. This seminal event  —  deciding which tar-
get to pursue, its level of   “  validation  ”   for a specifi  c medi-
cal condition and whether to pursue it with a small or 
large molecule, agonist or antagonist, etc.  —  triggers a 
number of downstream activities requiring substantial 
investments of time, personnel, and fi  nancial resources. 
The processes and events leading up to ion channel 
target selection are complex and vary widely across 
the pharmaceutical/biotechnology industries and aca-
demia. However, once an ion channel target has been 
selected, the approaches for its rigorous character-
ization are common, requiring a systematic, multidisci-
plinary effort spanning genetics, anatomy, biochemistry, 
cell biology, and electrophysiology. Although all candi-
date drug targets require detailed characterization in 
order to be pursued effectively, multisubunit ion chan-
nels are among the most challenging and, owing to the 
array of cell types, diversity of channel phenotypes and 
highly polarized neuronal architecture, CNS channels 
are particularly daunting. The aim of this Perspective is 
to describe some of the challenges to ion channel target 
    Abbreviations used in this paper: BK    , BK channel      subunit; KChIP, 
Kv channel interacting protein; Kv, voltage-gated potassium. 
characterization and selection for drug discovery, based 
on experiences within CNS drug discovery programs 
focused on neuronal voltage-gated K 
+   (Kv) channels. 
A cornerstone of these programs was the development 
of specifi  c, extensively characterized antibody reagents 
that could be used to generate detailed information on 
the distribution, subcellular localization, and molecu-
lar composition of individual channel complexes, as a 
basis for target selection and to help identify potential 
therapeutic applications for subtype-selective channel 
modulators (  Rhodes et al., 1996, 1997, 2004  ;   Bowlby 
et al., 2005  ). 
  Targeting Kv channels in the CNS is an extraordi-
narily challenging endeavor. In the ideal paradigm, one 
could select a Kv channel for drug discovery based on 
knowledge of its biophysical and pharmacological prop-
erties, association with specifi  c neurotransmitter systems 
and mode of dysregulation in CNS disease. This infor-
mation, coupled with an understanding of the channel ’  s 
subunit composition, would be used to construct a cell 
line expressing the component subunits that would be 
used to identify and characterize molecules that modu-
late channel activity. Knowledge of the channel  ’  s ana-
tomical distribution would guide selection of in vitro 
and in vivo pharmacology models, which would then be 
used to explore the consequences of channel modulation 
and further elucidate potential therapeutic utility. The 
anatomical and in vivo data might also reveal potential 
adverse consequences associated with modulating the 
target channel  ’  s activity. 
  Nevertheless, the process is rarely this simple. Al-
though it is possible to use conventional electrophysio-
logical recording techniques to characterize the basic 
biophysical and pharmacological properties of many 
neuronal Kv channels, the combinatorial assembly of 
voltage-sensing and pore-forming Kv      subunits, and 
their associated cytoplasmic Kv     subunits, leads to for-
mation of an incredibly diverse array of channel types 
(  Jan and Jan, 1997  ). This heteromultimeric assembly of 
subunits makes it extremely challenging to defi  ne na-
tive Kv currents in terms of component subunits that 
can then be expressed in heterologous cells to support 
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association with specifi   c neurotransmitter systems in 
mammalian brain. Although antibodies can play a critical 
role in all aspects of target validation for drug discovery, 
they are uniquely suited for studies of Kv channels 
owing to their potential for specifi  city, ability to work 
across a range of assay platforms, and the potential that 
the antibody reagents themselves may serve as pharma-
cological tools to characterize channel activity. However, 
the use of poorly characterized antibodies that do 
not have the requisite specifi  city for the target antigen 
or have not been fully validated for use in the intended 
application (e.g., immunohistochemistry, immunoprecip-
itation) has led to perpetuation of confl  icting and at 
times erroneous information. Although we recently 
documented steps that investigators can use to validate 
antibody reagents as tools to neuroscience discovery 
(  Rhodes and Trimmer, 2006  ), some of those points are 
worth restating here. 
  The generation and validation of antibodies with the 
desired effi  cacy and specifi  city has many parallels to the 
drug discovery process. The process involves selecting a 
specifi  c immunogen (i.e., the molecular entity used to 
immunize the source animal for antibody production). 
In the post-genomic era, these generally comprise syn-
thetic peptides or recombinant protein fragments, as 
opposed to subcellular fractions or proteins purifi  ed 
from native tissue. The design of immunogen, whether 
it be a synthetic peptide or recombinant protein, greatly 
impacts the downstream in vivo events that lead to the 
generation of a humoral immune response and the 
characteristics of antibody-producing cells and anti-
bodies, and the subsequent screening and purifi  cation 
steps required before the antibody reagents can be ap-
plied to target validation studies. While the design of im-
munogens is guided by considerations of the complexities 
of MHC-mediated antigen presentation and other im-
munological considerations, an overriding consider-
ation is whether the sequence used is likely to generate 
an antibody specifi  c for the target. For neuronal ion 
channel subunits, this can be a challenge as they are typ-
ically members of a large family of highly related poly-
peptides. The goal is to fi  nd a sequence that satisfi  es 
general considerations as to its potential to be on the 
solvent-accessible surface of the target protein  ’  s three-
dimensional structure, not present on other ion chan-
nel family members, and if possible, on any other protein 
in the mammalian proteome. For pAb production, this 
can usually be accomplished with a synthetic peptide, 
whose optimum size for immunogenicity and ease of 
synthesis ranges between 15 and 22 amino acids. Recom-
binant protein fragments are generally larger, given the 
practical diffi   culty of working with small cDNA frag-
ments needed to generate peptide-sized recombinant 
proteins. The larger recombinant proteins typically gen-
erate a more robust and varied humoral immune re-
sponse, yielding antibodies that work well across many 
drug screening. Adding further complexity is the ob-
servation that some Kv channels are targeted to distal 
dendrites, some are clustered along myelinated axons, 
and others are concentrated at nerve terminals (  Trimmer 
and Rhodes, 2004  )  —  all locations that are challenging 
to access by conventional electrophysiological record-
ing and therefore diffi  cult to study at a biophysical or 
pharmacological level. Finally, in cases where the native 
current can be characterized, it is not currently possible 
to recapitulate the subunit composition or stoichiome-
try of the native channel in a heterologous expression 
system. In combination, these challenges force a com-
promise between what we know about the native chan-
nel and what we can practically achieve in a cell-culture 
system. Nevertheless, for the purposes of screening 
and lead identifi  cation and drug discovery, knowledge 
of anatomical distribution and subunit coassociation, 
based on anatomical observations and coimmuno-
precipitation analyses, provides a good place to begin 
the process. 
  When we began our work on the pharmacology of 
K 
+   channels in the early 1990  ’  s, little was known about 
the physiology, biochemistry, and pharmacology of the 
native proteins. Initial reports identifying cDNAs and 
characterizing the conductance properties of Kv chan-
nel      subunits of mammalian Kv channels had just 
appeared (e.g.,   Chandy et al., 1990  ) and efforts were 
underway in many laboratories to correlate the ex-
pression of mRNAs encoding individual subunits with 
currents that had been recorded from cultured neu-
rons or brain slices (e.g.,   Koch et al., 1997  ). However, as 
these data emerged it became clear that there was not a 
1:1 correlation between the properties of Kv channel 
     subunits expressed individually in heterologous cells 
and the properties of currents recorded in native sys-
tems. In addition, because neurons are highly polarized 
cells, it was quickly appreciated that expression of 
mRNA at the soma was not informative as to the subcel-
lular location of the encoded protein and therefore 
could not provide insight into the potential role of the 
channel in neuronal physiology. As individual neurons 
were shown to express many distinct Kv subunits, it also 
became clear that mRNA localization had limited value 
as a tool to correlate subunit expression with Kv chan-
nel currents. Reagents to defi  nitively identify protein 
subunits and determine their abundance and distribu-
tion were required. 
  Presented with this challenge, we decided to use a 
comprehensive immunological and neuroanatomical 
approach that relied on an intensive effort to generate 
and characterize subunit-specifi  c  mouse  monoclonal 
and rabbit polyclonal antibodies (hereafter referred to 
as mAbs and pAbs, respectively) targeting individual 
channel subunits. We used these antibodies as tools to 
elucidate the subunit composition of Kv channels, re-
veal their subcellular distribution, and determine their   Rhodes and Trimmer 409
acteristics can yield a single   “  all-purpose  ”   reagent that 
can be applied to diverse immunohistochemical and 
biochemical procedures. While it is possible to obtain 
an all-purpose mAb, there are numerous examples of 
mAbs whose utility is restricted to a subset of (or even 
a single) applications, for example mAbs that work for 
immunoblotting or immunoprecipitation but not for 
immunohistochemistry. Within the heterogeneous col-
lection of antibodies in a pAb preparation may include 
those that have restricted utility, but the presence of 
a diverse repertoire can allow for coverage of all in-
tended applications. 
  An effective strategy for obtaining all-purpose mAbs is 
to start with a large pool (e.g., 50  –  100) of positive mAbs 
that have been identifi  ed as binding to the immunogen, 
for example in an ELISA assay. This increases the likeli-
hood that within this pool will be a mAb that fi  lls all 
needs. Generating large pools of positive mAbs is gener-
ally a refl  ection of the effectiveness of the immunization 
procedure. Our experience from   ≈  200 mAb projects is 
that recombinant protein fragments generate a more 
robust immune response than do synthetic peptides, 
and this yields a larger pool of ELISA-positive clones 
that can then enter the subsequent validation process. 
This is especially crucial for projects aimed at obtaining 
reliable mAbs for biochemistry and immunohistochem-
istry in native tissue. While most of the ELISA-positive 
clones will work fi  ne in recognizing the overexpressed 
target protein in heterologous expression systems (e.g., 
transfected cells), the number that exhibit effi  cacy and 
monospecifi  city in native tissues is generally much lower. 
An effective multistep screening strategy takes advantage 
of the high levels of expression of the target protein in 
transfected cells versus low or absent expression in un-
transfected cells in immunocytochemical and immuno-
blot assays as an initial confi  rmation that ELISA-positive 
clones recognize the target protein of interest. However, 
there is no substitute for rigorous and comprehensive 
assays in the relevant native tissue expressing the endog-
enous target, as this is where antibody-based target vali-
dation will be pursued. 
  Unlike transfected cells where expression can be ma-
nipulated by the investigator, and specifi  city easily con-
fi  rmed by comparing transfected versus untransfected 
cells, validation of specifi  city in native tissue, especially 
those with the complexity of mammalian brain, can be 
diffi  cult. As we reviewed previously (  Rhodes and Trimmer, 
2006  ), an effective approach is to compare patterns of 
mRNA expression derived from in situ hybridization 
analyses with the immunohistochemical staining pat-
tern obtained using antibody preparations. This can yield 
a pattern of cellular expression of a particular target 
mRNA that can be used to validate cellular specifi  city 
of antibody immunoreactivity. The brain offers unique 
challenges when applying this approach, as axonally 
localized proteins can be found at sites distant from the 
applications, but are more diffi  cult to design for speci-
fi  city of the resultant antibodies against the target of 
choice without potential for cross-reactivity against re-
lated family members. If fi  nancially and technically fea-
sible, it is advantageous to undertake both approaches 
in parallel. 
  A similar consideration holds for the decision to make 
pAbs versus mAbs. A phenomenal antibody of either 
kind is invaluable, poor versions of either can be prob-
lematic to the point of being virtually useless, or even 
worse, incredibly misleading. That said, there are a 
number of factors that can go into the choice of whether 
an intended project should be via the pAb or mAb 
route, although initiating both in parallel, as we did in 
our studies of Kv channels in CNS, greatly increases the 
probability of the ultimate goal, having a reliable re-
agent in hand for use in target validation. As far as the 
considerations, pAbs are present in antiserum obtained 
from the immunized animal and generally need to be 
purifi  ed from the serum before use. This can be a sig-
nifi  cant impediment to obtaining a monospecifi  c pAb 
that is simply not a factor for mAbs. The method of 
choice for purifying pAbs is affi  nity purifi  cation against 
the immunogen, as this allows for separation of specifi  c 
antibodies, which represent a minority of the total im-
munoglobulins in serum, from the excess of nonspecifi  c 
yet biochemically-similar immunoglobulin molecules 
present. For mAbs the monoclonal immunoglobulin is 
the only or predominant immunoglobulin in the prepa-
ration and can be effectively purifi  ed by standard pro-
tein biochemistry procedures (e.g., ammonium sulfate 
precipitation, ion exchange, or size exclusion chroma-
tography). Note that these steps are often employed as 
preliminary steps in affi  nity-based purifi  cation of pAbs. 
In the case of pAbs raised against recombinant protein 
immunogens, the affi  nity purifi  cation itself may require 
more than one step, as the immunogenic sequence may 
have segments specifi  c to the desired target and others 
representing sequences conserved in other family mem-
bers. A two-step affi  nity approach can lead to a selective 
enrichment of the former and depletion of the latter 
and yield a specifi  c antibody preparation. An alternative 
approach is to use the larger recombinant fragment for 
immunization, and a smaller fragment (recombinant 
or synthetic) representing the isoform-specifi  c region 
for affi  nity purifi  cation. While similar considerations 
are involved in choosing immunogens for mAb pro-
jects, there is substantially more fl  exibility in immuno-
gen design/choice, as downstream selection by strategic 
screening can identify and eliminate off-target or cross-
reacting mAbs. 
  Another consideration when choosing pAb versus 
mAb projects is the potential advantage of having a 
heterogeneous mixture of monospecifi  c antibodies in 
pAb preparations. The presence of a diverse reper-
toire of monospecifi  c antibodies with different char-410 Antibody-based Validation of CNS Ion Channel Drug Targets
immunoreactivity for the Kv channel interacting protein 
(KChIP) accessory subunits was dramatically reduced in 
regions where they associate with Kv4.2, but not where 
they associate with Kv4.3 (  Menegola and Trimmer, 
2006  ). For example, in hippocampi of Kv4.2    /     mice 
KChIP2 was down-regulated dramatically in CA1 neu-
rons, where it is normally found coassociated with Kv4.2. 
We have not found such effects in the Kv1.1 knockout 
mouse (  Wenzel et al., 2007  ). In general, incorporation 
of knockout mice into antibody validation procedures 
is a defi  nitive method of demonstrating specifi  city. 
However, as with other aspects of the drug discovery 
process, there remains a need to use this as only one 
(albeit compelling) step in a comprehensive and sys-
tematic multipronged validation process (  Rhodes and 
Trimmer, 2006  ). 
  Together, such a systematic approach to the genera-
tion and validation of antibody reagents can provide an 
investigator with a solid foundation to target validation 
in drug discovery. However, the reality is that drug dis-
covery efforts are often undertaken by groups without 
experience and expertise in these approaches, and 
where establishing such expertise is not deemed to be a 
justifi  ed investment in time, and in fi  nancial and hu-
man resources. In this case commercial antibody com-
panies offer an attractive source of antibodies against a 
wide array of potential drug targets. Such companies 
can have huge antibody catalogs (one recently adver-
tised antibodies against 31,000 different targets!) such 
that it is likely that an antibody against your intended 
drug discovery target exists in the commercial sphere. 
Moreover, these reagents are available to the end user 
without any intellectual property strings attached, 
which may not be the case with antibodies from other 
sources (e.g., academic laboratories). However, as with 
cell bodies that contain the mRNA. However, knowledge 
of brain anatomy and neuroanatomical connections 
is required to evaluate whether the mRNA expression 
patterns and immunostaining are consistent with one 
another. More recently, knockout and transgenic animals, 
typically mice, have emerged as an invaluable tool for 
validation of antibody specifi  city in native tissue. When 
available, a comparison of immunoreactivity in knockout 
and wild-type tissue by biochemical and immunohisto-
chemical approaches can allow for defi  nitive conclu-
sions as to the specifi  city of a given antibody signal. 
An example of such an analysis is shown in   Fig. 1  , where 
sections from wild-type and BK channel      subunit (BK    ) 
knockout mice (  Meredith et al., 2004  ) were stained with 
anti-BK     (L6/60, red;   Misonou et al., 2006  ) and anti-
Kv1.4 (K13/31, green;   Bekele-Arcuri et al., 1996  ) mAbs.   
The specifi  city of L6/60 staining to BK     in the hippo-
campus is evident by the lack of appreciable red signal 
in the section from the knockout animal.   Fig. 1   also 
shows representative immunoblot staining using L6/60 
against crude brain membranes prepared from rats, 
and from knockout and wild-type mice. Such experi-
ments can provide the investigator with a high level 
of confi  dence in the specifi  city of a given antibody in 
native tissue. Similar approaches can be used for valida-
tion of antibody specifi  city in other applications (e.g., 
immunoprecipitation, immunoelectron microscopy). 
Knockdown approaches using siRNA can provide a sim-
ilar confi  rmation. One caveat to the unfettered use of 
tissues from knockout animals for validation of antibody 
specifi  city is highlighted by our unexpected fi  nding that 
genetic deletion of one subunit of a multisubunit ion 
channel complex led to a dramatic down-regulation of 
the expression of other subunits in the complex. Stain-
ing of brain sections from Kv4.2    /     mice revealed that 
  Figure 1.     (Left panels) Double immunofl  uorescence 
staining of brain sections from wild-type and BK    knock-
out mice. Image shows the hippocampal fi  eld stained 
with mouse monoclonal anti-BK     L6/60 and anti-Kv1.4 
K13/31 antibodies. Isotype-specifi  c secondary antibod-
ies were used to visualize bound monoclonal antibod-
ies. Right panel shows an immunoblot performed with 
L6/60 on crude brain membranes from rats (RBM) and 
from wild-type (MBM-WT) and BK     knockout (MBM-
BK     KO) mice.       Rhodes and Trimmer 411
nels in hippocampal slice preparations facilitated action 
potential propagation and neurotransmitter release 
(  Halliwell et al., 1986  ). These observations suggested 
that selective blockers of Kv1 channels might have ther-
apeutic application in disorders characterized by im-
paired action potential propagation, such as multiple 
sclerosis, or reduced neurotransmitter release, such as 
Alzheimer  ’  s disease. However, we were also interested 
in Kv1 channels because of evidence that dramatically 
reduced activity of these subunits, by genetic mutation/
deletion of individual subunits (  Smart et al., 1998  ) or by 
application of high toxin concentrations, evoked sei-
zure activity (  Bagetta et al., 1992  ). This latter result in-
dicated that   “  openers  ”   or activators of Kv1 channels 
might have utility as anti-epileptic or perhaps even anx-
iolytic agents. However, at the outset of this work we did 
not know which of the dendrotoxin-sensitive Kv1 chan-
nels to target or which neurotransmitter systems might 
be affected through their modulation. 
  Upon generation of subunit-specifi  c antibodies for 
Kv1      and Kv     subunits, we were able to use single-and 
multiple-label immunohistochemical methods to deter-
mine that these subunits are predominantly localized 
along axons, where they are concentrated at nodes of 
Ranvier and in the preterminal axonal segments and 
axon terminals of glutamatergic and GABAergic path-
ways within the CNS (  Rhodes et al., 1995, 1996, 1997  ). 
In these locations, Kv1 channels are exquisitely posi-
tioned to regulate action potential propagation and 
neurotransmitter release. By using a strategy combining 
immunohistochemistry, immunoprecipitation, and se-
lective neurotoxin lesions, we demonstrated that chan-
nels containing Kv1.1, Kv1.2, Kv1.6, and Kv    2 were 
concentrated at nodes of Ranvier and were also present 
along unmyelinated axons and at axon terminals in 
many brain regions. Within the hippocampal forma-
tion, channels containing Kv1.1, 1.2, Kv1.4, and Kv    1 
subunits were concentrated along axons and in termi-
nal fi  elds of the perforant path, mossy fi  ber pathway, 
and Schaffer collateral pathways, where they presum-
ably regulate glutamatergic transmission within the tri-
synaptic hippocampal circuitry ( Monaghan et al., 2001 ). 
In biochemical analyses employing coimmunoprecipi-
tation of associated channel subunits and subsequent 
analyses by immunoblotting, we determined that in the 
sites where immunohistochemical staining for Kv1      
and Kv     subunits overlapped, the individual subunits 
were coassociated in heteromultimeric channel com-
plexes (  Rhodes et al., 1995, 1996, 1997  ). Although these 
and other studies provided evidence for a 1:1 associa-
tion of Kv1      and Kv     subunits within Kv1 channel com-
plexes (e.g., channels are       4        4   hetero-octamers), these 
studies would not allow for a determination of the precise 
stoichiometry of the individual Kv1      or Kv     subunits 
within the channel complexes. Nevertheless, by com-
paring the distribution and coassociation of individual Kv1 
all transactions, the phrase caveat emptor applies. While 
it is the obligation of the supplier to make an honest 
effort to validate any commercial antibody to the best of 
their ability, and to make absolutely clear to the end 
user what validation was performed, it is unreasonable 
to expect that a antibody company could possibly validate 
their products against anything but a small number of 
standard applications and preparations. That said, these 
should include determination of specifi  city against the 
endogenously expressed target in native tissues, and 
not simply assays against overexpressed exogenous 
target in heterologous cells. In this case companies 
focused on a single target area (e.g., neuroscience) may 
be better able to provide more extensive validation in 
specifi  c tissue type or application than a company with 
a broader focus. 
  To what extent the individual end-user should pursue 
additional validation is a matter of much discussion. It 
is unreasonable that after paying the high mark up that 
is typical of commercial antibody suppliers that an in-
vestigator should have to spend additional funds and 
effort on   “  quality control  ”   experiments that should have 
been done during antibody generation and validation, 
and before distribution. That said, should a reliable an-
tibody be necessary for key experiments aimed at evalu-
ating a target for a long-term drug discovery program, 
the fi  nancial repercussions could be enormous. The 
same care and attention to detail that goes into argu-
ably more familiar steps in the subsequent preclinical 
(pharmacology, medicinal chemistry, pharmacokinet-
ics, drug metabolism, cytochrome P450 interactions, 
etc.) and clinical (safety, effi  cacy, etc.) drug discovery 
process also apply to antibody-based target validation. 
Our perspective is that having in-house expertise in an-
tibody-based target validation, including generation of 
reliable antibody reagents and their effective use in im-
munohistochemical and biochemical analyses of the 
expression, localization, and coassociation of target ion 
channel subunits, is a justifi  ed investment as it repre-
sents a crucial fi  rst step in an overall drug discovery pro-
cess that may in total last many years and costs millions 
of dollars. 
  An example of this approach involving CNS ion chan-
nel drug targets comes from our studies of Kv channels. 
With well-validated antibody reagents in hand (  Bekele-
Arcuri et al., 1996  ), we were able to fi  rst perform an ex-
tensive series of immunohistochemical studies aimed at 
localizing individual Kv channel subunits to specifi  c cell 
types and neuroanatomical circuits within the mamma-
lian brain, with the goal of selecting specifi  c channel 
types/complexes for our drug discovery programs. Ini-
tially, we focused our attention on Kv1 channel subunits 
largely because selective pharmacological tools (e.g., 
the dendrotoxins) were already available to study this 
ion channel family. Pharmacological evidence indicated 
that application of     -dendrotoxin to block Kv1 chan-412 Antibody-based Validation of CNS Ion Channel Drug Targets
unit is concentrated in the somatodendritic domain of 
many neuronal types, where it is found in the apical 
dendritic arbors of hippocampal and neocortical pyra-
midal cells, and in the dendrites of striatal projection 
neurons and cerebellar granule cells (  Rhodes et al., 
2004  ;   Strassle et al., 2005  ). In these locations, Kv4.2 
coassociates predominantly with KChIP2 and/or KChIP3. 
Although Kv4.3 is also concentrated in the somatoden-
dritic domain of central neurons, its distribution only 
partially overlaps with Kv4.2. Rather, Kv4.3 immuno-
reactivity is concentrated in the apical dendritic arbors 
of specifi  c populations of cortical and hippocampal 
pyramidal cells, and in the dendritic arbors of cortical, 
hippocampal, and striatal interneurons, where it co-
localizes and coassociates with KChIP1 (  Rhodes et al., 
2004  ). Owing to the challenges associated with devel-
oping subunit-specifi  c Kv channel blockers and the rela-
tive lack of selective pharmacological tools for evaluating 
Kv4 channels, we pursued a strategy to modulate the ef-
fects of KChIPs on Kv4 currents. As KChIPs enhance 
Kv4 channel activity by increasing surface expression, 
slowing inactivation and slowing the rate of recovery 
from inactivation, we reasoned that a KChIP modulator 
would effectively block or inhibit Kv4 channel activity. 
Although screening for small molecule inhibitors of a 
protein:protein interaction is challenging, this program 
led to the identifi   cation of molecules that bind to 
KChIP1 and modulate its effects on Kv4 channel activity 
(  Bowlby et al., 2005  ). The therapeutic potential of these 
molecules is still under investigation. 
  Overall, the availability and use of high-quality anti-
body reagents adds tremendous value to the target 
validation process in drug discovery. For multisubunit, 
heteromeric ion channel targets in brain, these re-
agents are indispensable tools in the processes of target 
selection, characterization, and validation. Over the 
years, many of the assumptions we made about the 
therapeutic potential of subunit or subtype-specific 
channel modulators, based on anatomical localization 
and subunit coassociation of the target subunits as de-
termined by immunohistochemistry and coimmuno-
precipitation, were born out by the pharmacological 
tools that were identifi  ed through screening and sub-
sequent characterization. The example set by this pro-
cess of target identifi  cation and validation, based on 
a powerful combination of anatomical and immuno-
logical methods, has broad application within aca-
demic and industry drug discovery settings. The further 
application of these methods to studies of human 
brain tissue samples should facilitate development of 
more effective translational strategies in ion channel 
drug discovery. 
  We acknowledge our former and current colleagues for their nu-
merous contributions to the work described here, which was funded 
by National Institutes of Health grants NS34383 and NS42225 (to 
J.S. Trimmer), and by Wyeth Research. 
subunits in vivo with the results of electrophysiological 
studies that examined the currents produced by co-
expression of individual subunits in heterologous cells, 
we predicted that the currents formed by Kv1.1/Kv1.2/
Kv    2 subunits, in the absence of Kv1.4 or Kv    1, would 
have a delayed rectifi  er phenotype and high sensitivity 
to peptide toxins including     -dendrotoxin (  Trimmer 
and Rhodes, 2004  ). These channel complexes would be 
interesting targets for channel blockers where the goal 
is to facilitate conduction of action potentials and neu-
rotransmitter release. Channels containing Kv1.4 and/
or Kv    1 in addition to other Kv1-family      subunits 
would show less sensitivity to     -dendrotoxin and would 
have a rapidly inactivating phenotype. Based on their 
high densities within excitatory limbic circuits, we rea-
soned that activators or   “  openers  ”   of these channels 
might dampen excitability within these pathways and 
therefore have potential therapeutic utility in treating 
epilepsy or anxiety disorders. Although a compre-
hensive  discussion of the subsequent drug discovery 
strategy and outcome is well beyond the scope of this 
perspective, by expressing combinations of Kv1      and 
Kv     subunits in heterologous cells (CHO cell lines,   
Xenopus   oocytes, or yeast), we were able to screen for 
small molecule modulators of Kv1 channels and suc-
cessfully identify blockers of delayed-rectifi  er type Kv1 
channels, and compounds that slowed inactivation con-
ferred by the Kv    1 (  Zhang et al., 2004  ). This latter class 
of compounds, termed   “  disinactivators,  ”   showed intrigu-
ing in vivo pharmacological properties, having anti-
epileptic activity in rodent seizure models and anxiolytic 
activity in rodent models of behavioral confl  ict (  Zhang 
et al., 2004  ). 
  In subsequent studies in our laboratories, we took a 
similar approach but this time focused on Kv4 chan-
nels. At the time we initiated these studies, it was clear 
that Kv4 channels played an important role in regulat-
ing dendritic excitability in the CNS and that nonse-
lective inhibitors of Kv4 channel activity modulated 
synaptic strength within the hippocampal formation 
and neocortex (  Hoffman et al., 1997  ). We predicted 
that modulators (inhibitors) of these channels might 
facilitate long-term synaptic potentiation and provide 
a novel therapeutic approach to the treatment of Alz-
heimer  ’  s disease and other disorders characterized 
by age-related cognitive impairment. However, at the 
time we began this work, the subcellular distribution 
and subunit composition of native Kv4 channels was 
not well established. Using an approach similar to the 
one described above for Kv1 channels, we generated 
subunit-specifi  c antibodies for Kv4      subunits and also 
identifi  ed and characterized a family of accessory   “        ”   
subunits (KChIPs) for the Kv4 channel family (  An 
et al., 2000  ). Using the same combination of immuno-
histochemistry, coimmunoprecipitation, and selective 
neurotoxin lesions, we determined that the Kv4.2 sub-  Rhodes and Trimmer 413
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